Table 1.
A list of mAbs for asthma and AD discussed in the review are shown with some of their characteristics
| Name of the mAb | Trade name/company | Target of the mAb | Status/Effective | Indicaton |
|---|---|---|---|---|
| Omalizumab | Xolair (Genetech/Novartis) | IgE (Cε3 domain) | Commercially available | severe, persistent allergic asthma * chronic idiopathic urticaria § |
| QGE031 (ligelizumab) | Tanox/Novartis | IgE (Cε3 domain) | Phase II | allergic asthma (NCT01703312) ¶ AD (NCT01552629) ¶ chronic spontaneous urticaria (NCT02477332) ¶ |
| Dupilumab | Regeneron Pharmaceuticals/Sanofi‐Aventis | IL‐4 α receptor | Phase III | allergic asthma (NCT02414854) ¶ AD (NCT02277769) ¶ |
| Pascolizumab | GlaxoSmithLKline | IL‐4 | Phase II | symptomatic steriod‐naive asthma (NCT00024544) ¶ |
| Tralokinumab | Cambridge Antibody Technology/MedImmune | IL‐13 | Phase III Phase II | Uncontrolled asthma (NCT02161757) ¶ AD (NCT02347176) ¶ |
| Lebrikizumab | Tanox/Chugai Pharmaceutical | IL‐13 | Phase III Phase II | Uncontrolled asthma (NCT01987492) ¶ AD (NCT02340234) ¶ |
| Mepolizumab | Nucala (GlaxoSmithKline) | IL‐5 | Phase III terminated | Uncontrolled eosinophilic asthma (Mukherjee et al., 2014) (NCT01691521) ¶ |
| Reslizumab | Cinquil (Celltech R& D/Teva Pharmaceutical Industries) | IL‐5 | Phase III terminated | Uncontrolled eosinophilic asthma (NCT01285323) ¶ |
| Benralizumab | Kyowa Hakko/AstraZeneca; BioWa; MedImmune | IL‐5 α receptor | Phase III | Eosinophilic asthma (NCT02322775) ¶ |
| KB003 | KaloBios Pharmaceuticals | GM‐CSF | Phase II | Moderate‐to‐severe asthma (NCT01603277) ¶ |
| MEDI‐528 | Genaera Corporation; Ludwig Institute for Cancer Research/MedImmune | IL‐9 | Phase II | Uncontrolled asthma (Oh et al., 2013). |
| Brodalumab | Amgen Inc.; AstraZeneca/MedImmune | IL‐17A receptor | Phase II | Moderate‐to‐severe asthma (Busse et al., 2013) (NCT01199289) ¶ |
| AIN457 (secukinumab) | Novartis | IL‐17A | Phase II | Uncontrolled asthma (NCT01478360) ¶ |
| Ustekinumab | Centocor/Janssen‐Cilag | p40 submit of both IL‐12/IL‐23 | Phase II | AD (NCT01806662) ¶ |
| ILV‐094 | Pfizer/Wyeth | IL‐22 | Phase II | AD (NCT01941537) ¶ |
| BMS‐981164 | Bristol‐Myers Squibb; ZymoGenetics | IL‐31 | Phase I | AD (NCT01614756) ¶ |
| AMG282 | Amgen | IL‐33 | Phase I | Mild atopic asthma (NCT01928368) ¶ |
| AMG157 | Amgen/AstraZeneca | TSLP | Phase II Phase I | Uncontrolled asthma (NCT02054130) ¶ AD (NCT0075042) ¶ |
¶
https://clinicaltrials.gov/(ClinicalTrials.gov. Identifier).